Arvinas Starts ARV-6723 Dosing, Reports $558.9 Million in Liquidity
Photo: TokenPost
Arvinas has begun dosing patients in the monotherapy cohort of its ARV-6723 Phase 1/2 trial, advancing a program for advanced solid tumors with initial data expected in 2027. The company had $558.9 million in cash, cash equivalents, restricted cash and marketable securities as of Sept. 30, 2026, down from $685.4 million on Dec. 31, 2025. Under its current plan, that balance is expected to cover planned operating expenses and capital expenditures into the second half of 2028. Arvinas cautioned that the estimate depends on assumptions that may not hold and that it could use the funds sooner.
Source: TokenPost
